Washington State Prescription Drug Transparency Reporting: Data Definitions

Having trouble viewing this email? View it as a Web page.

Health Care Authority (HCA) logo

Washington State Prescription Drug Transparency Reporting: Data Definitions

The Health Care Authority (HCA) is writing you to follow up on our first drug price transparency reporting letter you should have received on Tuesday, May 5, 2020. In that letter we:

  • Briefly touched on the legislation requiring drug price reporting.
  • Described how to register as a required submitter (and how to request exemption or unsubscribe if applicable.)
  • Addressed “next steps” – which included receiving this letter for more information.

What do I need to do?

Review draft data definitions

HCA has finished the draft data definitions and made them available for review.

If you have not already done so…

  • Please confirm that you are the correct recipient of these notifications by registering as a data submitter. If you are not the correct contact in your organization, please forward this to the responsible person so they may register.
  • Download, complete, and return the submitter registration form.
  • Please do this as soon as possible but no later than August 1, 2020 as failure to submit registration information could delay your ability to be in compliance with RCW Chapter 43.71C.

What can I expect next?

HCA is working on the data submission guide, and will send another notification in late June or early July to inform you that it is ready for download.

Questions?

Please stay connected with us via our drug price transparency webpage. Here you can receive updates and contact us via email.